An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022)
{{output}}
Introduction: Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, has emerged as a promising drug target for multiple cancers. Up to now, a total of seven ALK inhibitors have been app... ...
